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Background: To analyze the tumor control, survival outcomes, and toxicity after stereotactic radiosurgery (SRS) for
skull base metastases from systemic cancer involving the anterior visual pathway.
Patients and methods: We have analyzed 34 patients (23 females and 11 males, median age 59 years) who
underwent multi-fraction SRS for a skull base metastasis compressing or in close proximity of optic nerves and
chiasm. All metastases were treated with frameless LINAC-based multi-fraction SRS in 5 daily fractions of 5 Gy each.
Local control, distant failure, and overall survival were estimated using the Kaplan-Meier method calculated from
the time of SRS. Prognostic variables were assessed using log-rank and Cox regression analyses.
Results: At a median follow-up of 13 months (range, 2–36.5 months), twenty-five patients had died and 9 were
alive. The 1-year and 2-year local control rates were 89% and 72%, and respective actuarial survival rates were 63%
and 30%. Four patients recurred with a median time to progression of 12 months (range, 6–27 months), and 17
patients had new brain metastases at distant brain sites. The 1-year and 2-year distant failure rates were 50% and
77%, respectively. On multivariate analysis, a Karnofsky performance status (KPS) >70 and the absence of extracranial
metastases were prognostic factors associated with lower distant failure rates and longer survival. After
multi-fraction SRS, 15 (51%) out of 29 patients had a clinical improvement of their preexisting cranial deficits. No
patients developed radiation-induced optic neuropathy during the follow-up.
Conclusions: Multi-fraction SRS (5 x 5 Gy) is a safe treatment option associated with good local control and
improved cranial nerve symptoms for patients with a skull base metastasis involving the anterior visual pathway.
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Radiation-induced optic neuropathyIntroduction
The base of the skull is a less common site of metastases;
however, they represent a clinical challenge as growing le-
sions in such area that compress optic nerve, chiasm, and
nerves involved in the extraocular movement have been
associated with serious morbidity [1]. Therapeutic options
include radiotherapy, chemotherapy, and surgery. Surgical* Correspondence: gminniti@ospedalesantandrea.it
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unless otherwise stated.resection is reserved for a minority of well-selected pa-
tients, depending on the accessibility of the lesion and
the potential morbidity of the procedure [2]. Similarly,
chemotherapy may have a role only in a subset of pa-
tients with chemosensitive or hormonosensitive lesions
[3]. Palliative radiotherapy with doses of 20–30 Gy in 5–
10 fractions results in significant symptom improvement
[4-9], although in clinical practice many physicians prefer
to withhold whole brain radiation therapy (WBRT) since
it may result in a decline of neurocognitive function and
quality of life [10,11].Ltd. This is an Open Access article distributed under the terms of the Creative
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for nearly 30 years in patients with a limited number of
brain metastases, is an effective treatment associated
with excellent local control without compromising sur-
vival, and potentially avoiding the risk of the detrimen-
tal neurocognitive effects of WBRT [12,13]. Few series
including either skull base metastases or head and neck
cancers have reported a 1-year local control of 53%-89%
after single-fraction SRS [14-17]. However, single large
doses may be associated with an increased risk for
neurologic morbidity from radiation necrosis [18-20],
and this is of concern especially for lesions larger than
2.5-3.0 cm or of any size that are in close proximity to
critical structures, such as the optic apparatus or brain-
stem in case of metastases of the skull base. Thus, multi-
fraction SRS (up to 5 fractions) has been employed in
patients with brain metastases as an alternative to single-
fraction SRS with the aim to reduce late radiation-induced
toxicity while maintaining high local control rate. Differing
from single-fraction SRS where patients have been trad-
itionally immobilized in an invasive frame, a stereotactic
mask is usually employed for multi-fraction SRS with a
setup accuracy of 0–3 mm. In patients with brain metasta-
ses multi-fraction SRS at doses of 27–42 Gy in 3–5 frac-
tions has resulted in 1-year local control of 70-90% with
acceptable radiation-induced toxicity [21-25], although the
efficacy and safety of this approach in patients with a skull
base metastasis remains to be determined.
In the present study we reviewed our experience with
SRS given in five daily fractions in patients with skull base
metastases from systemic cancer involving the anterior
visual pathway. Local control, neurologic outcome and risk
of radiation-induced neuropathies have been evaluated.
Patients and methods
Patient population
Patient data were obtained from a prospectively main-
tained database of patients with brain tumors treated
with brain stereotactic irradiation at our institution. We
identified 34 consecutive patients who received multi-
fraction SRS for a sellar and/or parasellar metastasis
adjacent or compressing the optic chiasm and/or optic
nerves derived from different histologically confirmed
systemic cancers. They represent the 2.3% of all patients
with brain metastases treated with SRS between March
2005 and August 2013 at University of Rome Sapienza,
Sant’Andrea Hospital. All patients were aged 18 years or
older with no prior WBRT. Informed consent was ob-
tained from all patients prior to treatment. The protocol
was approved by the Institutional Review Board.
Treatment
All metastases were treated with frameless LINAC-based
multi-fraction SRS given in 5 daily fractions of 5 Gy.Based on the linear quadratic model 25 Gy SRS (5 x
5 Gy) is probably ’biologically equivalent’ to approximately
a single-fraction SRS of 15 Gy assuming an α/β ratio of
10 Gy for the tumor, although with a potential de-
creased risk of damage to normal brain, including brain-
stem, optic nerves and chiasm (α/β ratio of 1–3 Gy).
Patient immobilization was achieved by using a com-
mercially available head mask fixation system (Brainlab
AG, Feldkirchen, Germany), together with a mouth bite
positioned against the upper dentition and attached to
the stereotactic frame. The characteristics of the system
and the technique have been previously described [26].
The target volumes were identified on the basis of the
fused CT and magnetic resonance image (MRI) scans. The
gross tumor volume (GTV) was delineated as a contrast-
enhancing tumor demonstrated on MRI scans. The plan-
ning target volume (PTV) was generated by the geometric
expansion of GTV plus 1–2 mm. Doses were prescribed
to the 80-90% isodose line normalized to the maximum
dose, performed to ensure coverage of at least 95% of the
PTV with the prescription dose (Figure 1). Treatment
volumes were achieved with 6–15 noncoplanar conformal
beams by using a BrainLAB m3 micromultileaf collimator
attached to a Varian Clinac 600 DBX. Patients were treated
in 5 consecutive days in outpatient clinic. Dexamethasone
therapy was started by the first day of treatment at doses
of 4 mg PO per day and maintained for one week after the
end of treatment.
Follow-up
Patients were examined clinically before SRS and then
every 2 months. At each visit, neurological status and
the severity of complications were rated according to the
National Cancer Institute (NCI) Common Terminology
Criteria for Adverse Events v4.0 (CTCAE) central nervous
system toxicity. Ophthalmologic examinations including
visual acuity assessment and visual field testing were per-
formed every 3 months. MRI was made every 2 months in
the first year after treatment, and then every 3 months or
as appropriate according to the neurological conditions.
Complete response was defined as total radiographic
disappearance of enhancing lesion, partial response as
shrinkage of tumor volume >50%, and stable disease as
reduction in the tumor volume ≤50%. Local progression
was defined as radiographic increase in the volume of
metastatic lesion on serial imaging. In patients with sus-
pected local progression, dynamic susceptibility-weighted
contrast-enhanced (DSC) perfusion MRI and 3,4-dihy-
droxy-6-[18]F-fluoro-l-phenylalanine ([18]F-FDOPA) PET/
CT were used for differential diagnosis between recurrent
tumor and radiation-induced brain necrosis. Distant
intracranial progression was defined by presence of new
brain metastases or leptomeningeal enhancement out-
side the irradiated volume. All images were reviewed by
Figure 1 Prescription isodose distribution in axial and coronal views of a skull base metastasis compressing the optic chiasm
(contoured in yellow). The planning target volume (contoured in blue) was created by the geometric expansion of tumour plus 1 mm. The
patient was treated with a linear accelerator (LINAC) multi-fraction stereotactic radiosurgery (5 x 5 Gy) with the use of 8 noncoplanar conformal
beams. The dose was prescribed to the 87% isodose line normalized to the maximum dose, with a minimum PTV coverage of 98%. The isodose
curves showing dose levels delivered to surrounding tissues and adjacent critical structures are represented.
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performed by using the BrainLab iPlan treatment plan-
ning software and changes in tumor volume were calcu-
lated after fusion of pre-treatment and post-treatment
MRI scans. Metastatic lesions were manually contoured
by the same radiation oncologist (G.M) using postcon-
trast axial T1-weighted images with 1 mm slice thick-
ness. For all patients who died, the cause of death
(intracranial versus extracranial progression) was deter-
mined by clinical/neurological evaluation and brain/
systemic radiologic studies.
Local control, distant failure, and overall survival were
estimated using the Kaplan-Meier method calculated
from the time of multi-fraction SRS. For univariate ana-
lysis, the log-rank test was used for categorical variables,
and the Cox proportional hazards model was used for
continuous variables. The multivariate Cox proportional
hazards regression model was used to test the independ-
ent effect of significant prognostic factors at univariate
analysis (p <0.05).Results
Patient and treatment characteristics
Between March 2005 and August 2013, 34 patients who
underwent multi-fraction SRS for a skull base metastasis
adjacent or compressing the optic chiasm and/or optic
nerves were evaluated in this study. Patients and tumor
characteristics are summarized in Table 1. Twenty-three
(67%) patients presented with a single skull base metas-
tasis and 11 (33%) patients had also 1–2 brain metasta-
ses in other brain locations that were treated with SRS(8 patients) or surgery plus SRS (2 patients). At SRS, ex-
tracranial disease was absent in 13 patients. Twenty-
nine had cranial nerve deficits, including optic nerve
(reduced acuity in 7 and visual field defects in 9), oculo-
motor (n = 10), abducens (n = 9), trigeminal (n = 5), and
facial (n = 2) deficits. Twenty patients received chemo-
therapy during the post-SRS follow-up. All patients re-
ceived the planned dose 25 Gy delivered in 5 daily
fractions. The median minimum PTV coverage was 97%
(range, 95-100%). Median prescription isodose was 86%
(82%-90%) and median conformity index was 1.61 (range
1.28-2.12). Data were reported to January 2014. At this
time 25 patients had died.
With a median follow-up of 13 months (range, 2–
36.5 months), crude local control was achieved in 30 cases
(88%). Based on Kaplan-Meier analysis, the 1-year and
2-year local control rates were 89% and 72%, respect-
ively (Figure 2). A complete response was achieved in 3
patients and partial response 14 patients, respectively.
Four patients recurred with a median time to pro-
gression of 12 months (range, 6–27 months). Eighteen
patients had new brain metastases at distant sites. The
median distant metastases-free survival time was 12 months
(range, 2–36 months) (Figure 3). The 1-year and 2-year
actuarial incidence rates of new distant brain metastases
were 50% and 77%, respectively. The median survival
time was 14.5 months (95% CI, 12.0 -17.0 months), and
1-year and 2-year actuarial survival rates were 63% and
32%, respectively (Figure 4). Seventy-six percent of
patients succumbed to their extracranial disease and
24% of patients died of progressive intracranial disease
at either local (n = 1) and/or distant sites (n = 5).
Table 1 Summary of patient characteristics
Parameter No (%)
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Figure 3 Kaplan-Meier estimate of distant disease-free survival.
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distant metastases-free survival rates are shown in Table 2.
On multivariate analysis the absence of extracranial me-
tastases (P = 0.01; HR 0.18, 95% CI 0.07-0.64) was the only
variable associated with lower distant failure rates. No fac-
tors, including histology, tumor volume and conformityindex had impact on local control. The absence of ex-
tracranial metastases (p = 0.001; HR 0.1, 95% CI 0.05-
0.40) and KPS >70 (p = 0.01; HR 0.30, 95% CI 0.1-0.68)
were independent favorable prognostic factors for over-
all survival.Neurologic function and toxicity
Cranial deficits were present in 29 (85%) out of 34 pa-
tients. After multi-fraction SRS, fifteen (51%) patients
had a clinical improvement of neurological deficits. Vision
acuity and/or visual fields defects improved in 7 patients,
oculomotor deficits in 10 patients, trigeminal deficits in 2
patients, and facial palsy in one patient. The maximum
and median doses to the optic chiasm, optic nerve, and
cavernous sinus are showed in Table 3. The optic
chiasm was < 2 mm away or in contact with the tumor
in 10 and 8 patients, respectively. The median volume
receiving > 5 Gy and the maximum dose to the optic
chiasm were 0.13 cm3 and 5.7 Gy, respectively. No pa-
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Figure 4 Kaplan-Meier estimate of overall survival.
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http://www.ro-journal.com/content/9/1/110One patient had a transient 6th nerve palsy 12 months
after SRS with full recovery after a short course of corti-
costeroids. For this patient the maximum radiation dose
was 27.5 Gy (5.5 Gy each fraction) to the cavernous
sinus. Three patients experienced neurological deficits
(motor deficits in 2 patients, ataxia in one patient, and
speech deficits in one patient) that regressed with the
use of corticosteroids. Neurological deterioration was
associated with intracranial progression at distant sites
in all patients. Salvage treatment consisted of further
SRS (n = 10) or surgery (n = 3) in 13 patients and WBRT
(30 Gy in 10 daily fractions over two weeks) in 7 pa-
tients. Median survival after WBRT was 6.3 months
(range 1.8-13.5 months). No patients developed cranial





Sex, male vs female male (16.1); female (1
Age (years), < 65 vs ≥ 65 < 65 (15.0); ≥ 65 (11
KPS, ≤ 70 vs >70 ≤ 70 (11.5); >70 (20
Primary tumor, breast cancer vs others breast cancer (13.0); othe
Extracranial metastases, absent vs present absent (22.5); present
Number of metastases, 1 vs > 1 1 met (15.5); >1 met (
Distant brain failure
Sex, male vs female male (16.1); female (1
Age (years), < 65 vs ≥ 65 < 65 (12.0); ≥ 65 (10
KPS, ≤ 70 vs >70 ≤ 70 (8.0); >70 (16.
Primary tumor, breast cancer vs others breast cancer (10.0); othe
Extracranial metastases, absent vs present absent (18.0); present
Number of metastases, 1 vs > 1 1 met (16.0); > 1 met
KPS, Karnofsky Performance Status.Discussion
Palliative RT has been the standard treatment for skull
base malignancies providing excellent relief of pain and
improvement of cranial nerve dysfunction in up to 78%
of patients [4-9]. More recently, SRS has been employed
as a less invasive option for the treatment of skull base
metastases with the aim to deliver a high dose to the target
with dose sparing of critical structures such as the optic
nerves and chiasm. The efficacy of single-fraction SRS for
skull base metastases has been reported in few studies that
include either nasopharyngeal carcinomas or skull base
metastases [14-17]. Iwai et al. [15] treated 21 patients with
cavernous sinus cancers, including 12 patients with me-
tastases from systemic cancer. At a median follow-up of
13 months, the 1-year and 2-year tumor control rates
were 68% and 47%, respectively, with no significant dif-
ferences between nasopharyngeal carcinoma and metas-
tases. After SRS, there was a resolution or improvement
of preoperative cranial nerve deficits in 47% of patients.
Kano et al. [17] reviewed retrospectively 37 patients
with cancer involving the cavernous sinus treated with
gamma knife SRS at the University of Pittsburgh between
1992 and 2006. At median follow-up of 9 months the
progression-free survival rates after SRS were 77.6% and
26.6% at 1 and 2 years, respectively. Lower marginal doses
were associated with shorter progression-free survival, as
in case of tumors in close proximity to the optic pathway
or larger lesions; the progression-free survival rate was
89.7% for patients receiving a marginal dose ≥ 15 Gy as
compared with 35.9% for those receiving < 15 Gy. Ap-









.3) 0.001 0.30 (0.1-0.68) 0.01
rs (15.5) 0.2




0) 0.03 0.36 (0.16-1.27) 0.1
rs (14.0) 0.1
(8.0) 0.002 0.18 (0.07-0.64) 0.01
(10.0) 0.1
Table 3 Median radiation doses to cavernous sinus, optic nerves and chiasm in patients treated with multi-fraction SRS
(5 × 5 Gy)
Site Median Maximum Organ at risk Volume (cm3) Volume (cm3)
dose dose volume receiving receiving
(Gy) (Gy) (cm3) a dose > 25.0 Gy a dose > 27.5 Gy
Cavernous sinus 18.5 29 1.9 (1.44-2.52) 1.7 (1.41-2.4) 0.52 (0.2-1.9)
Optic nerve 13.5 28.5 0.93 (0.71-1.26) 0.08 (0.01-0.5) 0.026 (0.005-0.08)
Optic chiasm 5.5 (12*) 28.5 0.48 (0.33-0.71) 0.13 (0.03-0.28)* 0.022 (0.01-0.06)*
*In 18 patients receiving a total dose to the optic chiasm >25 Gy.
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few series [14,16].
Multi-fraction SRS represents an alternative to single-
fraction SRS for relatively large brain metastases > 3 cm
or adjacent to critical structures with a reported local
control rates of 65-90% at 1 year [21-25]. In the current
study we have evaluated 34 patients with a skull base
metastasis compressing or in close proximity of the vis-
ual pathway who were treated with multi-fraction SRS
(5 × 5 Gy). The 1-year and 2-year survival rates were
63% and 32%, and respective actuarial 1-year and 2-year
local control rates were 89% and 69%, which are in the
best range of results observed after single-fraction SRS
[14-17] and fractionated stereotactic radiotherapy [27].
A tumor local control of 66-76% at 1 year has been
reported following multi-fraction SRS with 5 × 5–7 Gy
in patients with brain metastases [21-25]. Ernst-Stecken
et al. [22] reported the treatment results of a prospect-
ive study of multi-fraction SRS (5 x 6–7 Gy) in 51 pa-
tients with 72 brain metastases. At a median follow-up
of 7 months the 1-year local control was 76% and sur-
vival 60%, respectively. Using a median prescribed dose
of 25 Gy with a median of 5 fractions Kwon et al. [25]
observed a similar actuarial local tumor control rates of
94% and 68.2% at 6 months and 1 year, respectively, in
36 patients with 66 brain metastases. While the optimal
dose and fractionation for brain metastases remain to
be determined, our results indicate that multi-fraction
SRS with 5 × 5 Gy is an effective treatment for skull
base metastases associated with good local control and
improvement of cranial deficits similar to that reported
after single-fraction SRS.
The main reason for using multi-fraction SRS is the
advantage of fractionation with respect to radiobiology
and normal brain protection. Single-fraction SRS for
skull base lesions is in fact limited by the potential tox-
icity of high single doses to the cranial nerves. While
the reported tolerance of cranial nerves in the cavern-
ous after single-fraction SRS sinus is of 16–18 Gy [28],
several retrospective studied have indicated that the in-
cidence of radiation-induced optic neuropathy is about
2% for doses of 8–12 Gy, and becomes >10% for doses
of 12–15 Gy [28-31]. Leavitt et al. [31] have recentlyreviewed 222 patients treated with Gamma Knife SRS
for benign tumors adjacent to the anterior visual path-
way. The risk of optic neuropathy was 0 for patients
receiving a maximum dose of 8–12 Gy and 10% for those
receiving >12 Gy, respectively, suggesting that small
portions of anterior visual pathway in the range of 0.02-
0.04 cm3 may receive doses up to 12 Gy. In our study
no optic neuropathy were observed for doses >25 Gy to
less than one-third of optic chiasm and > 27.5 Gy to a
small volume of 0.01-0.06 cm3. These point doses may
serve as baseline for future comparison when evaluating
the risk of optic neuropathy after SRS using different
schedules.
The present study has some limitations. The small num-
ber of patients and the relatively short follow-up do not
allow for definitive conclusions about the risk of symp-
tomatic optic neuropathy when using multi-fraction SRS.
Further studies and larger number of patients are needed
to confirm that patients receiving doses >25 Gy to the
optic nerve and chiasm had a low risk of developing clinic-
ally symptomatic radiation optic neuropathy. Nevertheless,
our results suggest that when single doses to the anterior
optic pathway exceeds 10–12 Gy, as for large skull base
metastases or for those adjacent to the optic apparatus,
multi-fraction SRS may represent an alternative to single-
fraction SRS with similar local control and lower risk of
treatment-related complications.
The 1-year and 2-year distant failure rates were 50%
and 77%, necessitating salvage treatment with SRS in
ten and WBRT in seven patients, respectively. Overall,
WBRT could be avoided in about 75% of patients. The
main justification for omitting WBRT is that it is associ-
ated with a decline in quality of life and neurocognitive
function [10-13] without conferring survival advantages
[12,13]. In a randomized study of 58 patients with 1 to 3
metastases who received WBRT plus SRS or SRS alone,
Chang et al. [13] observed that patients treated with
SRS plus WBRT showed a greater risk of a significant
decline in learning and memory function at 4 months as
compared with patients who received SRS alone. Sun
et al. [11] reported similar neurocognitive impairment
in patients with small cell lung carcinoma who received
prophylactic WBRT. In our study the high distant failure
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due to intracranial progression and neurological impair-
ment, confirming that the omission of up-front WBRT is
not detrimental for these patients. However, a close MRI
follow-up is mandatory with the intent to treat early new
distant brain metastases to avoid any potential neurocog-
nitive deterioration.
In conclusion, multi-fraction SRS using 5 × 5 Gy is a
feasible treatment option associated with good local
control and improvement of cranial nerve symptoms in
patients with a skull base metastasis involving the anter-
ior visual pathway. A maximum dose less than 28.5 Gy
delivered in 5 fractions to a small portion of the optic
nerves and chiasm is associated with a very low risk of
radiation-induced optic neuropathy.
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